Biotech Values

[mcbio]

Re: ANTH - in-licensing of lead drug

I confirmed my suspicions as ANTH did in fact in-license several of its product candidates, including its lead drug in Phase 3 targeting ACS. See: http://investor.anthera.com/releasedetail.cfm?ReleaseID=424037 which details the in-license agreement with LLY and Shionogi in September 2006.